Lilly Gives Investors A Glimpse At Post-2014 Balance Sheet
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly says R&D and SG&A spending will decline as a percent of sales post-2014, likely resulting in spending cuts, when the company expects to return to sales growth after cycling through important patent losses.
You may also be interested in...
Lilly Claims It’s On Pace To Traverse Its Patent Cliff, Meet Financial Guidance Through 2014
As it prepares for the U.S. patent expiration of blockbuster antidepressant Cymbalta later this year, Lilly says it is meeting three strategic priorities it set in 2009, putting it on a path to return to sustainable growth.
Emerging Markets 2012 First Half Earnings Roundup
A mixed first half and second quarter for big pharmas in emerging markets, as companies did well in select countries, notably China, but faced economic downturns and generics elsewhere.
Emerging Markets 2012 First Half Earnings Roundup
A mixed first half and second quarter for big pharmas in emerging markets, as companies did well in select countries, notably China, but faced economic downturns and generics elsewhere.